Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy
Open Access
- 10 November 2022
- journal article
- research article
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 9, 138-145
- https://doi.org/10.33393/grhta.2022.2474
Abstract
Objective: Conventional synthetic disease modifying antirheumatic drugs (csDMARDs) were recommended in 2019 as first line therapy from Italian Medicines Agency (AIFA) for the treatment of moderate to severe psoriasis. Updated local guidelines recommended methotrexate (MTX) as the drug of first choice. Nevertheless, MTX is reported by AIFA to be underused. Since no study evaluated jointly the first-line efficacy and costs of the most widely used biologic drugs (adalimumab, etanercept, secukinumab and ustekinumab) and methotrexate in Italy, a cost per responder (CPR) analysis was performed. Methods: A CPR model was developed based on efficacy data from a published Cochrane network meta-analysis.Drug costs included in the model were estimated based on average regional tender prices. The primary analysisassessed the CPR of both Psoriasis Area and Severity Index (PASI) 90 at weeks 12 and 52. A secondary analysis was conducted considering PASI 75. For methotrexate, both an average dosage of 13.4 mg, estimated by an expertpanel, and a dosage of 15 mg reported in European guidelines were considered. Results: At weeks 12 and 52, the costs per responder PASI 90 were lower for methotrexate 13.4 mg compared to the most widely used biologics in Italy, € 566.71 and € 2,455.72 respectively. Methotrexate also showed a lowest CPR both at 12 and 52 weeks, € 529.95 and € 2,296.47 respectively, in the secondary analysis. Conclusions: The analysis showed a lower cost per responder for methotrexate than for adalimumab, etanercept,secukinumab and ustekinumab. For healthcare budget holders, this means using the saved resources to treat more patients.Keywords
This publication has 20 references indexed in Scilit:
- Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasisDermatologic Therapy, 2019
- Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in ItalyGlobal and Regional Health Technology Assessment, 2019
- Epidemiology of Psoriasis and Psoriatic Arthritis in Italy—a Systematic ReviewCurrent Rheumatology Reports, 2018
- Reaching complete or near-complete resolution of psoriasis: benefit and risk considerationsBritish Journal of Dermatology, 2017
- Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasisJournal of the European Academy of Dermatology and Venereology, 2017
- Ixekizumab for the Treatment of Psoriasis: A Review of Phase III TrialsDermatology and Therapy, 2016
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJournal of the American Academy of Dermatology, 2015
- PsoriasisCold Spring Harbor Perspectives in Medicine, 2014
- Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in GermanyActa Dermato-Venereologica, 2010
- Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in GermanyDermatology, 2008